Floatz logo

Mva-Bn-Brachyury

Prostate Adenocarcinoma

University of UtahvaccinePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

97 Active assets in the Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 2BB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB
Degarelix
Canadian Cancer Trials Group
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB

View all 50 →

Same molecule, other indications

Mva-Bn-Brachyury is also rated in:

castration-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
prostate neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →